A Phase Ib Study of Camrelizumab in Combination with Apatinib and Fuzuloparib in Patients with Recurrent or Metastatic Triple-Negative Breast Cancer
BMC Medicine（2022）
关键词
Camrelizumab,Apatinib,Fuzuloparib,TNBC,PARP,VEGFR,PD-1,Triple-negative breast cancer,Immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要